相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading
Jordan M. Spatz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
An RNA-seq Protocol to Identify mRNA Expression Changes in Mouse Diaphyseal Bone: Applications in Mice with Bone Property Altering Lrp5 Mutations
Ugur M. Ayturk et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
The sclerostin-bone protein interactome
Hemamalini Devarajan-Ketha et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Early Response of Bone Marrow Osteoprogenitors to Skeletal Unloading and Sclerostin Antibody
Mohammad Shahnazari et al.
CALCIFIED TISSUE INTERNATIONAL (2012)
Osteoporosis-Pseudoglioma Syndrome: Three Novel Mutations in the LRP5 Gene and Response to Bisphosphonate Treatment
B. Tuysuz et al.
HORMONE RESEARCH IN PAEDIATRICS (2012)
Characterization of the Interaction of Sclerostin with the Low Density Lipoprotein Receptor-related Protein (LRP) Family of Wnt Co-receptors
Gill Holdsworth et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes
Paul J. Niziolek et al.
BONE (2011)
Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model
XiaoYan Tian et al.
BONE (2011)
Lrp5 and Lrp6 redundantly control skeletal development in the mouse embryo
Kyu Sang Joeng et al.
DEVELOPMENTAL BIOLOGY (2011)
Anabolic and Catabolic Regimens of Human Parathyroid Hormone 1-34 Elicit Bone- and Envelope-Specific Attenuation of Skeletal Effects in Sost-Deficient Mice
Alexander G. Robling et al.
ENDOCRINOLOGY (2011)
Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG)
C. M. Laine et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2011)
Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator Function
Olivier Leupin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Single-Dose, Placebo-Controlled, Randomized Study of AMG 785, a Sclerostin Monoclonal Antibody
Desmond Padhi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Teriparatide Increases Bone Mineral Density in a Man With Osteoporosis Pseudoglioma
Henrique Pierotti Arantes et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Inhibition of Sclerostin by Monoclonal Antibody Enhances Bone Healing and Improves Bone Density and Strength of Nonfractured Bones
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Lrp5 functions in bone to regulate bone mass
Yajun Cui et al.
NATURE MEDICINE (2011)
Dissecting Molecular Differences between Wnt Coreceptors LRP5 and LRP6
Bryan T. MacDonald et al.
PLOS ONE (2011)
Wnt Antagonists Bind through a Short Peptide to the First β-Propeller Domain of LRP5/6
Eric Bourhis et al.
STRUCTURE (2011)
Sclerostin binds and regulates the activity of cysteine-rich protein 61
Theodore A. Craig et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Sclerostin-erbB-3 interactions: Modulation of erbB-3 activity by sclerostin
Theodore A. Craig et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats
XiaoYan Tian et al.
BONE (2010)
Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia
Anne Saarinen et al.
CLINICAL ENDOCRINOLOGY (2010)
Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee
A. Michael Parfitt et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
The Societal Burden of Osteoporosis
David J. Becker et al.
Current Rheumatology Reports (2010)
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Lrp4, a Novel Receptor for Dickkopf 1 and Sclerostin, Is Expressed by Osteoblasts and Regulates Bone Growth and Turnover In Vivo
Hong Y. Choi et al.
PLOS ONE (2009)
Osteoporosis-pseudoglioma syndrome: Description of 9 new cases and beneficial response to bisphosphonates
Elizabeth A. Streeten et al.
BONE (2008)
The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations
Wendy Balemans et al.
CALCIFIED TISSUE INTERNATIONAL (2008)
Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd
Takuo Kubota et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Factors associated with 5-year risk of hip fracture in postmenopausal women
John Robbins et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
PTH stimulates bone formation in mice deficient in Lrp5
Urszula T. Iwaniec et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025
Russel Burge et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST
Mikhail V. Semenov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity
Debra L. Ellies et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment
Kimihiko Sawakami et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor
M Semënov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling
XF Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins
DG Winkler et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex
DG Winkler et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6
SL Holmen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
High bone mass in mice expressing a mutant LRP5 gene
P Babij et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
DG Winkler et al.
EMBO JOURNAL (2003)
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor
M Kato et al.
JOURNAL OF CELL BIOLOGY (2002)
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development
YQ Gong et al.
CELL (2001)
分享论文
